Health Care • Biotechnology: Pharmaceutical Preparations
$0.68 ▲ +0.00
(+0.22%)
MKT CAP: $13.4M • VOL: 46.9K
52W L $1 52W H $4
ROARABLE / RQD
D • 44/100
PIOTROSKI
4 / 9
DARE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.0M | $9.8K | $2.8M |
| YoY Revenue Growth % | +10429.4% | -99.7% | — |
| Gross Profit | $734.4K | $9.8K | — |
| Gross Margin % | 71.3% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$13.6M | -$23.5M | -$30.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$13.4M | -$4.0M | -$30.2M |
| EBITDA (Normalized) | -$13.2M | -$23.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.9M | $5.5M | -$38.9M |
| Capital Expenditures (CapEx) | $385.3K | $573.0K | — |
| Free Cash Flow (FCF) | -$10.3M | $4.9M | -$38.9M |
| FCF Margin % | -80.0% | 80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $24.7M | $15.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.8M | -$6.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DARE.